Experienced in Miller-Fisher Syndrome

Dr. Mark M. Mckenzie

Internal Medicine
6031 Shallowford Rd, Suite 105, 
Chattanooga, TN 
Experienced in Miller-Fisher Syndrome
6031 Shallowford Rd, Suite 105, 
Chattanooga, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Mckenzie is a primary care provider, practicing in Internal Medicine in Chattanooga, Tennessee. Dr. Mckenzie is rated as an Experienced provider by MediFind in the treatment of Miller-Fisher Syndrome. His top areas of expertise are Guillain-Barre Syndrome, Chronic Polyradiculoneuritis, Miller-Fisher Syndrome, and Athlete's Foot.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in TN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO

Locations

6031 Shallowford Rd, Suite 105, Chattanooga, TN 37421

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia
Enrollment Status: Completed
Publish Date: December 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 2
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway
Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 2/Phase 3
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Enrollment Status: Active_not_recruiting
Publish Date: September 20, 2024
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
Enrollment Status: Completed
Publish Date: August 18, 2023
Intervention Type: Drug
Study Drug: Setmelanotide
Study Phase: Phase 2
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
Randomized, Multicenter, Double-blind, Parallel-Group, Placebo & Comparator-Controlled Study to Compare the Glycemic Effects, Safety & Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus
Randomized, Multicenter, Double-blind, Parallel-Group, Placebo & Comparator-Controlled Study to Compare the Glycemic Effects, Safety & Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Suspended
Publish Date: March 14, 2023
Intervention Type: Drug
Study Drug: Metformin
Study Phase: Phase 3
A Phase 1, Multi-Center, Open-Label, Safety and Tolerability Study of Intravenous Administration of ST266 in Subjects With Confirmed COVID-19 Infection
A Phase 1, Multi-Center, Open-Label, Safety and Tolerability Study of Intravenous Administration of ST266 in Subjects With Confirmed COVID-19 Infection
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Biological
Study Drug: ST266
Study Phase: Phase 1
View 9 Less Clinical Trials

3 Total Publications

Clinical performance of Abbott ID NOW™ COVID-19 2.0 rapid molecular point-of-care test compared to three real-time RT-PCR assays.
Clinical performance of Abbott ID NOW™ COVID-19 2.0 rapid molecular point-of-care test compared to three real-time RT-PCR assays.
Journal: Microbiology spectrum
Published: February 11, 2025
Similar Doctors
Experienced in Miller-Fisher Syndrome
Dr. Jason A. Kilmer
Internal Medicine
Experienced in Miller-Fisher Syndrome
Dr. Jason A. Kilmer
Internal Medicine

Hospital Medicine Services Of Tn LLC

941 Spring Creek Rd, 
Chattanooga, TN 
 (4.3 miles away)
423-894-7870
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Kilmer is a primary care provider, practicing in Internal Medicine in Chattanooga, Tennessee. Dr. Kilmer is rated as an Advanced provider by MediFind in the treatment of Miller-Fisher Syndrome. His top areas of expertise are Stroke, Hartnup Disease, Inborn Renal Aminoaciduria, Gastrostomy, and Hip Replacement. Dr. Kilmer is currently accepting new patients.

Experienced in Miller-Fisher Syndrome
Dr. Carroll G. Odem
Internal Medicine
Experienced in Miller-Fisher Syndrome
Dr. Carroll G. Odem
Internal Medicine
5600 Brainerd Rd, Suite FC 5, 
Chattanooga, TN 
 (3.6 miles away)
423-400-9910
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carroll Odem is a primary care provider, practicing in Internal Medicine in Chattanooga, Tennessee. Dr. Odem is rated as an Advanced provider by MediFind in the treatment of Miller-Fisher Syndrome. His top areas of expertise are Chronic Pain, Hypertension, Glucocorticoid-Remediable Aldosteronism, Cardiac Ablation, and Endoscopy. Dr. Odem is currently accepting new patients.

Experienced in Miller-Fisher Syndrome
Dr. Subhash P. Virani
Internal Medicine
Experienced in Miller-Fisher Syndrome
Dr. Subhash P. Virani
Internal Medicine

Memorial Health Partners Foundation, Inc

5600 Brainerd Rd, Suite 500, 
Chattanooga, TN 
 (3.6 miles away)
423-414-3586
Languages Spoken:
English, Bahasa, Hindi
See accepted insurances
Accepting New Patients

Subhash Virani is a primary care provider, practicing in Internal Medicine in Chattanooga, Tennessee. Dr. Virani is rated as an Advanced provider by MediFind in the treatment of Miller-Fisher Syndrome. His top areas of expertise are Sepsis, Peptic Ulcer, Acute Pancreatitis, Endoscopy, and Gastrostomy. Dr. Virani is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mckenzie's expertise for a condition
ConditionClose
        View All 20 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile